Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV)....
To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI).
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, announced the label revisions of ViiV Healthcare’s four HIV drugs to update the caution against their administration for patients with renal dysfunctions
Merck & Co. Inc. has announced that the FDA has approved two new HIV-1 medicines, Delstrigo and Pifeltro (doravirine) (MK...